The Role of Erythropoietin in Preventing Anemia in the Premature Neonate.
AOP
EPO
RBC transfusions
anemia
anemia of prematurity
erythrocyte transfusions
erythropoietin
rhEPO
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
09
10
2023
revised:
21
11
2023
accepted:
22
11
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
epublish
Résumé
Recombinant human erythropoietin (rhEPO) treatment is an alternative to red blood cell (RBC) transfusions in neonates presenting anemia of prematurity (AOP). This study assesses the impact of early rhEPO administration on AOP (any stage) incidence, as well as the incidence of individual AOP stages and RBC transfusions. Out of 108 preterm neonates, 49 were administered rhEPO and compared to the remaining group using univariate and multivariate analyses. Univariately, gestational age (GA), birth weight (BW), hemoglobin (Hb), hematocrit (HCT), RBC levels, and iron administration were significantly associated with AOP (
Identifiants
pubmed: 38136044
pii: children10121843
doi: 10.3390/children10121843
pii:
doi:
Types de publication
Journal Article
Langues
eng